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Mediators of Inflammation 4, 426-430 (1995)
LONG-TERM treatment with inhaled corticosteroids
has been shown to result in improvement of
symptoms and lung function in subjects with
asthma. Arachidonic acid (AA) metabolites are
thought to play a role in the pathophysiology of
asthma. It was assessed whether differences could
be found in bronchoalveolar lavage (BAL) AA
metabolite levels between subjects with asthma
who were treated for 2.5 years with inhaled
bronchodilators alone or in combination with
inhaled corticosteroids. Prostaglandin (PG)D2,
PGF2, 6-keto-PGFa, thromboxane B2, leuko-
triene (LT)C and LTB levels and cell numbers
were assessed in BAL fluid from 22 non-smoking
asthmatic subjects. They were participating in a
randomized, double-blind multicentre drug trial
over a period of 2.5 years. Results of the group
treated with inhaled corticosteroids (CS+: beclo-
methasone 200g four times daily) were
compared with the other group (CS-) which was
treated with either ipratropium bromide (40g
four times daily) or placebo. BAL LTC levels of
asthmatic subjects were significantly lower after
2.5 years inhaled corticosteroid therapy (CS+,
9(1-17)pg/ml vs. CS-, 16(6-53) pg/ml; p 0.01).
The same trend was observed for the PGD2 levels.
The results suggest that inhaled corticosteroids
may exert their beneficial effect on lung function
via a mechanism in which inhibition of LTC
synthesis in the airways is involved.
Key words: Arachidonic acid metabolites, Asthma,
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Introduction
Recent long-term studies on the prognosis and
morbidity of obstructive airways disease have
shown that addition of inhaled corticosteroids to
maintenance treatment with a 2-agonist in
hyper-responsive patients with obstructive
airways disease leads to a significant reduction of
respiratory symptoms, exacerbation rates, airway
12obstruction and airway hyper-responsiveness.
These findings are thought to be a consequence
of suppression of inflammatory processes in the
airways.
No single cell type or mediator in the inflam-
matory processes in the airways is responsible
for the clinical events in asthma. Nevertheless,
there is now substantial evidence that arachi-
donic acid (AA) metabolites play an important
role in the pathophysiology of the disease. They
are potent airway constrictors, increase mucus
secretion, play a role in chemotaxis and may
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enhance airway responsiveness, one of the char-
acteristics of the disease. A role for AA metabo-
lites in the modulation of severity of asthma is
suggested by the presence of higher levels in
BAL fluid as compared to those in healthy sub-
jects, increasing even more after allergen provo-
cation.4,5
One potential mode of action of inhaled corti-
costeroids involves the modulation of arachi-
donic acid (AA) metabolite levels in the airways.
They may decrease AA metabolite synthesis by
their inhibitory effect on phospholipase A2 or by
inhibition of synthesis of cytokines that stimulate
AA metabolite release. In order to assess the role
of AA metabolites in the effects of long-term
treatment of asthmatic subjects with corticoster-
oids, AA metabolite levels in bronchoalveolar
lavage (BAL) fluid were assessed in a subgroup
of non-smoking asthmatic patients who partici-
pated in a randomized, double-blind multicentre
drug trial for 2.5 years.
(C) 1995 Rapid Science Publishers
LTC4 levels after corticosteroid therapy
Materials and Methods Correlations between BAL data and lung func-
tion parameters obtained 1 week preceding the
Patient selection: Before entering the multicentre bronchoscopy procedure were investigated. The
drug intervention trial, patients were selected study protocol was approved by the medical
based on: (1) Baseline FEV larger than 1.21 ethics committees of the participating hospitals.
(ranging between 4.5 and 1.6 residual standard All patients gave written informed consent.
deviations below the predicted value), or an
FEV1/inspiratory vital capacity (IVC) ratio lower Pulmonary function and inhalation provocation
than 1.64 RSD below the predicted value, pro- tests.. FEV was performed on water-sealed spi-7
vided that total lung capacity was higher than rometers according to standardized guidelines,
1.64 RSD below the predicted level; (2) airway before and 20 min after four single inhalations of
hyper-responsiveness to histamine, defined as the 250 l-tg of terbutaline administered through a 750-
provocative concentration of histamine that ml spacer device (Nebuhaler). Histamine provo-
caused 20% decrease in FEV (PC20) 8 mg/ml; cation tests were performed using a 2 min tidal
and (3) exclusion of pregnant women, patients breathing method, as described previously. Mea-
with a history of occupational asthma or other surements were made only during clinical stable
serious diseases, patients who used oral corticos- periods, and not within 4 weeks after the termi-
teroids, 13-blockers, nitrates, or anticoagulants, nation of a course of prednisolone. All pulmon-
and patients who continuously used antibiotics, ary medications were discontinued 8 h before
each test.At enrolment, the subjects were assigned to
one of three double-blind regimens using iden- Bronchoalveolar lavage: Fibre optic broncho-
tical metered dose inhalers: all patients received scopy (Olympus B1 IT10, Tokyo, Japan) was
an inhaled 132-agonist (terbutaline 500 l.tg) com- undertaken according to guidelines of the Amer-
bined with either an inhaled corticosteroid ican Thoracic Society.8 Premedication consisted(beclomethasone dipropionate 200 btg), an of intramuscular injection of 0.5 mg atropine andinhaled anticholinergic (ipratropium bromide inhalation of 5001.tg terbutaline 30 min before401.tg) or an inhaled placebo. All medication was the procedure. Lidocaine 4% was administered
taken four times daily, into the upper airways and bronchial tree.
Bronchoalveolar lavage was performed with
Study design.. AA metabolites and cell numbers 1 x 30ml (pool 1) and 4 x 50ml (pool 2)
were analysed in BAL fluid obtained from out- sterile phosphate-buffered saline (PBS) at 37C
patients from two university pulmonary depart- with the bronchoscope wedged in the lateral
ments (Groningen and Rotterdam), 2.5 years segment of the fight middle lobe. After recovery
after participation in the above-indicated rando- by gentle suction (-40cm H20), the BAL fluid
mized, double-blind multicentre drug interven- was collected in a siliconized specimen trap
tion trial. At the time of selection of patients for placed on melting ice.
this study and bronchoscopy the patients were Immediately after collection of the BAL fluid
still receiving their trial medication. Therefore, the laboratory procedures were carried out. The
the investigators were blind to the treatment that BAL fluid was centrifuged at 400 x g at 4C for 5had been received in the preceding 30 months, min. BAL supernatant was separated from the cell
Analysis was performed only in BAL fluid pellet. The cell pellets were washed in PBS sup-
obtained from 22 non-smoking patients with plemented with 0.5% heat-inactivated bovine
asthma, diagnosed by criteria from a standar- serum albumin (BSA). Total leukocyte numbers
dized history of respiratory symptoms and with in BAL cell suspensions were counted in a
a reversibility of airways obstruction > 9% of Coulter Counter and viability was assessed by
FEV1% predicted at entry, cellular exclusion of trypan blue. Cell differentials
In accordance with findings in all participants were done on May-GrOnwald-Giemsa stained
of the trial, no significant differences in FEV cytocentrifuge preparations. At least 500 cells
values, reversibility of airway obstruction and were counted.
airway responsiveness to histamine obtained at
the last visit preceding the bronchoscopy proce- AA metabolite determination: Immediately after
dure were found between asthmatic patients the BAL procedure, 20ml of BAL supernatant
assigned to the placebo and anticholinergic from pool 2 was processed on C18 SepPak car-
groups. Therefore, differences in BAL para- tridges (Millipore, Bedford, USA)as described
meters in this study were investigated between previously,9 eluated with 2.5ml methanol and
the groups without (i.e. placebo + anti- stored at -80C until analysis. Samples of 200 l.tl
cholinergic therapy) and with inhaled corticos- BAL eluted fluid were pipetted into polypropylene
teroid therapy, tubes and dried with a Savant sample con-
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Table 1. Patient characteristics and lung function parameters at entry in the study, according
to treatment group
Characteristic CS- CS p
Number 13 9
Gender, M/F 11/2 5/4 N.S.
Age, years 36 (23-55) 43 (31-60) N.S.
Diagnosis, asthma/
asthmatic bronchitis 10/3 6/3 N.S.
Blood eosinophils (x 106/I) 200 (79-631) 251 (18-501) N.S.
Atopy* 13+ 7+/2 N.S.
Total IgE (IU/ml) 120 (18-1000) 110 (4-1000) N.S.
FEV1% pred. 62 (38-90) 60 (46-84) N.S.
FEV1/VC 55 (38-68) 55 (43-65) N.S.
Reversibility (FEV1% pred.) 16.6 (9-31.2) 16.4 (9-27.3) N.S.
PC2o histamine (mg/ml) 0.14 (0.01-0.79) 0.16 (0.03-3.2) N.S.
Med=ans with range.
CS- and CS asthma groups treated without and with inhaled corticosteroids, respectively. *Atopy as
determined by positive results of intracutaneous tests against house dust mite or two other tested common
aeroallergens.
Table 2. Lung function parameters at the last visit just before bronchoscopy, according to
treatment group
Parameter CS- CS p
Blood eosinophils x 106/I) 152 (59-616) 130 (22-309) N.S.
FEVl % pred. 56 (31-87) 88 (56-99) 0.002
FEVl/VC 51.6 (28.9-68.4) 60.6 (53.6-75.4) 0,01
Reversibility (FEV1% pred.) 19.0 (-0.6-36.9) 8.5 (--3.5-19.9) 0.01
PC2o histamine (mg/ml) 0.06 (0.02-0.87) 1.46 (0.1-14.4) 0.001
Medians with range. CS- and CS asthma groups treated without and with inhaled corticosteroids, respectively.
centrator. After dissolving in 300 I.tl assay buffer,
levels of thromboxane B2 (TxB2), and leukotriene
B4 (LTB4) were determined by means of a [3H]-
RIA with antisera from Advanced Magnetics Inc.
(Cambridge, MA) and [H]-labelled compounds
from Amersham International (Buckinghamshire,
UK). Levels of prostaglandins (PG) D2 and PGF2a
were determined with commercially available
[H]-kits (Amersham, UK) and 6-kPGF with a[125I]-RIA kit (Du Pont de Nemours, Dreieich,
Germany), according to the manufacturer’s
instructions. Leukotfiene C4/D4/t4 (EWe4) was
measured at room temperature in a microtitre
enzyme immunoassay according to the manufac-
turer’s protocol (Biotrak, Amersham, UK). The
cross-reactivity of the LTC4 antibody with LTD4
was 100% and with EWE4, 30%. Cross-reactivities
for the other assays to related compounds were
negligible or less than 2% at B/Bo 50%.
Data analysis.. Values are presented as medians
with ranges. Spirometry data were analysed with
Student’s t-test. Bronchoalveolar lavage data were
not normally distributed and therefore analysed
with the Mann-Whitney U test. Correlations were
made using Spearman’s rank correlation tests. All
analyses were performed with the SPSS/PC + V
4.01 software package (SPSS Inc., Chicago, IL).
Values of p < 0.05 were considered statistically
significant.
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Results
Subjects: Patient characteristics and lung function
parameters at entry in the study in the groups
with (CS +, n 9) and without (CS-, n 13)
corticosteroid treatment are listed in Table 1.
Comparing group data at entry in the trial retro-
spectively, no significant differences in patient
characteristics and lung function parameters were
found between the groups. In contrast, after 2.5
years of double-blind, randomized treatment, a
significant improvement in FEV1, reduction in
reversibility of airway obstruction and reduction
in airway responsiveness to PC20 histamine were
found in the CS + as compared to the CS-
group (Table 2).
BAL cell numbers and levels ofAA metabolites:
The percentage recovery of BAL fluid was sig-
nificantl higher in the CS + than in the CS-
group (p 0.01). There were no significant dif-
ferences in median total or differential cell
numbers/ml BAL fluid between the groups
(Table 3). The median LTC4 level in the CS +
group was significantly lower than the level in
the CS- group (p= 0.01), while the median
PGD2 level showed the same trend (Table 4).
The levels of the other investigated AA metabo-
lites were not significantly different between the
CS + and CS- groups.
LTC4 levels after corticosteroid therapy
Table 3. Effect of inhaled corticosteroids on BAL fluid volume and cell numbers (pool 2)
Parameter CS- CS p
Recovery % 34 (10-68) 63 (33-72)
Total leukocytes x 103/ml 85 (14-212) 123 (26-431)
Alveolar macrophages 79 (9-180) 99 (21-349)
Lymphocytes 3 (0 15 7 (0 78)
Neutrophils (0-19) 2 (0- 7)
Eosinophils (0-9) 0 (0-4)








Table 4. BAL AA metabolite levels (pg/ml)
Metabolite CS- CS p
PGD2 77 (15-200) 28 (17-138) 0.12
PGF2= 19 (5-25) 15 (5-36) N.S.
6-kPGFI= 16 (8-30) 13 (7-24) N.S.
TxB2 71 (1-141) 42 (3-149) N.S.
LTC4 16 (6-53) 9 (1-17) 0,01
LTB4 75 (15-138) 96 (23-279) N.S.
Medians with range. CS- and CS asthma groups treated without and
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FIG. 1. Relation of BAL LTC4 and PGD2 levels on FEV1% pre-
dicted in asthmatic subjects treated with inhaled corticosteroids
(closed circles) and asthmatic subjects treated with inhaled 12-
agonists alone (open circles). For details, see text.
Correlation with lung function: EWe4 levels cor-
related significantly with FEV1 % pred.
(rho -0.46, p=0.03) (Fig. 1). PGD2 levels
correlated significantly with FEV1 % pred.
(rho -0.62, p 0.002), as did PC20 histamine
(rho -0.50, p= 0.02) and the reversibility of
airways obstruction (rho -0.52, p 0.01).
Discussion
This study started from the hypothesis that
suppression of inflammatory processes in the
airways underlies the improvement in lung func-
tion observed after long-term treatment with
inhaled corticosteroids. AA metabolite levels are
considered as biochemical markers of on-going
chronic airway inflammation in the airways of
asthmatic subjects.-5 Therefore, we investigated
whether differences in BAL AA metabolite levels
could be detected between subjects treated with
[2-agonists and inhaled corticosteroids for 2.5
years and those treated with inhaled 2-agonists
alone. Results from this study show that the BAL
LTC4 levels are significantly lower in asthmatic
patients treated with inhaled corticosteroids. The
same trend is observed for PGD2 levels. The
median BAL AA metabolite values of the corticos-
teroid treated group were within the same level as
those from a control group of eight non-smoking,
non-atopic healthy subjects who were con-
currently analysed during the same procedure,m
This is the first study in which AA metabolite
levels were measured after long-term treatment
with inhaled corticosteroids. In contrast to our
results, short-term treatment with prednisolone
60mg/day has been reported to have no sig-
nifican effect on BAL fluid AA metabolite levels
in asthmatic subjects, although the in vitro synth-
esis of AA metabolites by BAL cells was
decreased. A lower production of LTC4 by BAL
cells was also found in asthmatic subjects who
had been treated for more than 2 years with 5-
15 mg prednisone,2 which is in line with our
results. A role for cysteinyl leukotrienes in the
pathophysiology of asthma is suggested by find-
ings that leukotrienes induce airway obstruction,
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increase airway hyper-responsiveness and
increase mucous secretion. After oral treatment
with a leukotriene D4 receptor antagonist a sig-
nifican reduction in asthma symptoms and
improvement of lung function has been reported
in asthmatic subjects. In the light of current
knowledge, several mechanisms can be postu-
lated to explain the reduced LTC4 levels in the
CS-treated group. First, corticosteroids exert a
decreased cellular AA metabolite synthesis by
inhibiting phospholipase A2 activation through
the generation of lipocortin.4 Results from this
study suggest that cells that predominantly
release LTC4 (eosinophils, alveolar macrophages,
mast cells) are more sensitive to corticosteroid
treatment. Secondly, corticosteroids may selec-
tively inhibit the transcription of cytokines from
airway cells6’5’6 that may regulate LTC4 release.
IL-3, ILo5 and GM-CSF have been shown to prime
human basophils, eosinophils and neutrophils
for augmented release of LTC4 after stimulation
by a second agonist.17-19
Results of this study suggest an effect of long-
term corticosteroid treatment on BAL PGD2
levels as well. PGD2 is a potent airway constrictor
and is implicated in the increase in airway
responsiveness. PGD2 is synthesized by a variety
of airway cells. It has been observed that the in
vitro PGD2 synthesis by human lun2 mast cells
was not affected by glucocorticoids. The PGD2
synthesis by human alveolar macrophages upon
stimulation by calcium ionophore A23187 was,
however, significantly inhibited by methyl pre-
dnisolone.21 If in vitro results can be extra-
polated to the in vivo situation, the results favour
a role for PGD2 release by alveolar macrophages
in the chronic inflammatory process in asthma.
We did not find a difference in total or differ-
ential cell numbers between the groups. Previous
findings in studies on the effect of short-term
corticosteroid treatment (6 weeks to 4 months)
on BAL cell numbers are not consistent, although
in the majority a reduction of BAL eosinophil
numbers was found.15’16’22’23 It cannot be exclu-
ded that we did not find differences as a con-
sequence of group sizes that were too small.
Inflammatory processes in the airways are,
however, probably better reflected by cell activa-
tion than increased cell numbers in the BAL
fluid, as has been found in this study.
In conclusion, this study shows that BAL LTC4
levels of asthmatic subjects were significantly
lower after 2.5 years inhaled corticosteroid
therapy. The results suggest that corticosteroids
may exert their beneficial effect on lung function
via a mechanism in which inhibition of LTC4
synthesis in the airways is involved.
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